DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. ("Patheon" or the "company") today announced the pricing of the initial public offering of 29,761,905 of its ordinary shares at a public offering price of $21.00 per share. Patheon is selling 25,000,000 ordinary shares and the selling stockholder named in the prospectus is selling 4,761,905 ordinary shares. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 4,464,286 ordinary shares from the company.
The ordinary shares of the company are scheduled to begin trading on the New York Stock Exchange on July 21, 2016 under the symbol "PTHN". The offering is expected to close on or about July 26, 2016, subject to customary closing conditions.
The company intends to use the net proceeds it receives from the offering and cash on hand to repay all of its outstanding $550 million of Senior PIK Toggle Notes, pay related fees and expenses and accrued interest. Patheon will not receive any proceeds from the sale of ordinary shares by the selling stockholder.
J. P. Morgan, Morgan Stanley, Jefferies and UBS Investment Bank are acting as lead book-running managers and representatives of the underwriters for the offering. Credit Suisse, Evercore ISI and Wells Fargo Securities are acting as joint book-running managers for the offering. Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners are acting as co-managers for the offering.
The offering will be made only by means of a prospectus. The prospectus relating to the offering may be obtained from:
|J. P. Morgan Securities LLC||Morgan Stanley & Co. LLC|
|c/o Broadridge Financial Solutions||180 Varick Street, Second Floor|
|1155 Long Island Avenue||New York, New York 10014|
|Edgewood, New York 11717||Attn: Prospectus Department|
|Attn: Prospectus Group|
|Telephone: (866) 803-9204|
|Jefferies LLC||UBS Securities LLC|
|520 Madison Avenue, 2nd Floor||1285 Avenue of the Americas|
|New York, New York 10022||New York, New York 10019|
|Attn: Equity Syndicate Prospectus Department||Attn: Prospectus Department|
Telephone: (888) 827-7275
|Telephone: (877) 547-6340|
A registration statement relating to these securities has been filed and declared effective with the U.S. Securities and Exchange Commission ("SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
The statements in this press release that are not historical facts may be forward-looking statements. Such forward looking statements, based upon the current beliefs and expectations of Patheon's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. Accordingly, readers should not place undue reliance on forward-looking statements as a prediction of actual results. For more information concerning factors that could cause actual results to differ materially from those conveyed in the forward-looking statements, please refer to the "Risk Factors" section of the prospectus included in the registration statement, in the form last filed with the SEC. Patheon does not assume any obligation to update the information contained in this press release.
About Patheon N.V.
Patheon is a leading global provider of pharmaceutical development and manufacturing services. With approximately 8,000 employees worldwide, Patheon provides a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle.Contacts
Mari Mansfield, 919-226-3137
Patheon Investor Relations, 919-226-3165